Εκπαιδευτικά προγράμματα
Λίστα αντικειμένων

Βρείτε επισυναπτόμενη την εκπαιδευτικη παρουσίαση του Καθ. Αλέξανδρου Σπυριδωνίδη Transplant in Ph- B ALL στο 5ο Εκπαιδευτικό Σεμινάριο στη Μεταμόσχευση Μυελού των Οστών και τις Κυτταρικές Θεραπείες: Απόψεις και Αντιπαραθέσεις, 12-13 Μαίου 2023, Αθήνα, Ξενοδοχείο Crowne Plaza
Ομιλητής: Καθ. Α Σπυριδωνίδης
Συμμετέχοντες:
Moνάδα Μεταμόσχευσης Μυελού...


See the attached the educational slides of Prof Spyridonidis presentation at 49th EBMT annual meeting, Paris
2023_GVHD prophylaxis in matched sibling donor transplant_PTCY_Spyridonidis


Presenter: Prof. Spyridonidis
Participants: Dr Liga, Dr Tsokanas
Duration: 40 mins
Defibrotide plus best standard of care compared with best
standard of care alone for the prevention of sinusoidal
obstruction syndrome (HARMONY): a randomised,
multicentre, phase 3 trial


49 Annual Meeting of the EBMT - 23-26 April, 2023, Paris France
Relapse remains a major cause of failure after allogeneic hematopoietic cell trnaplantation (allo-HCT).
Prophylactic donor lymphocyte infusion (pDLI) could be used to reduce relapse.
However, its widespread application has been restricted...


49 Annual Meeting of the EBMT - 23-26 April, 2023, Paris France
Though a randomized study suggested the benefit of in vivo T-cell depletion (TCD) as Graft versus Host Disease (GvHD) prophylaxis in matched sibling donor (MSD) allogeneic hematopoietic cell transplantation...


March 19–March 22, 2023
Munich, Germany
https://www.dropbox.com/s/10uojri60ijyazs/Leukemia%20MUnich%20selected.pptx?dl=0


Presenter: Prof. Spyridonidis
Participants: Dr Liga, Dr Tsokanas
Duration: 40 mins
The optimal selection of patients with acute myeloid leukemia (AML) for allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an area of research that continues to evolve.1 For patients with favorable-risk AML who achieve...


Presenter: Prof. Spyridonidis
Participants: Dr Liga, Dr Tsokanas
Duration: 35 Mins
Understanding how genetic variants impact molecular phenotypes is a key goal of functional genomics,
currently hindered by reliance on a single haploid reference genome. Here, we present the EN-TEx resource
of 1,635 open-access datasets...


1. Lesson Plan_Pre-clinical studies design
2. Pre-clinical studies - An overview - Ariel Angel 11.2022
3. Tech Transfer


Presenter: Prof. Spyridonidis
Participants: Dr Liga, Dr Tsokanas
Duration:40mins
https://www.bloodtransfusion.it/bt/article/view/332


https://www.cancertherapyadvisor.com/home/cancer-topics/hematologic-cancers/hematologic-cancers-treatment-regimens/leukemia-treatment-regimens-acute-lymphoblastic-leukemia-all/
NCCN recommends cancer patient participation in clinical trials as the gold standard for treatment.
Cancer therapy selection, dosing, administration, and the management of related adverse events can be a complex process that should be handled by an experienced healthcare team. Clinicians...


Presenter: Prof. Spyridonidis
Participants: Dr Liga, Dr Tsokanas
Duration: 40mins
Axicabtagene ciloleucel is an engineered autologous anti-CD19 chimeric
antigen receptor T cell therapy being developed for patients with refractory aggressive B-cell lymphoma. The product is manufactured in a central
facility from cellular starting material containing...


Presenter: Prof. Spyridonidis
Participants: Dr Liga, Dr Tsokanas
Duration: 40 mins
In this registry-based study, we compared outcomes of allogeneic hematopoietic cell transplantation (allo-HCT) in adult patients with
acute lymphoblastic leukemia (ALL) transplanted in first complete remission (CR-1), following conditioning with total body irradiation...


Administration and handling of cell product
Management of Adverse Events
Patient card


Find attached the article ''To Transplant or Not To Transplant in First Remission Acute Lymphoblastic Leukemia? Study group data give some answers, but not all.'' authored by Prof. Spyridonidis and published at American Society for Transplantation and Cellular Therapy


Presenter: Prof. Spyridonidis
Participants: Dr Liga, Dr Tsokanas, Dr Valera
Duration: 40 mins
Historically, Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) has been associated with poor outcomes, and allogeneic hematopoietic cell transplantation (alloHCT) is recommended in first complete remission (CR1). However, in the...


Presenter: Prof. Spyridonidis
Participants: Dr Liga, Dr Tsokanas, Dr Valera
Duration: 35 mins
With the introduction of large-scale molecular profiling methods and high-throughput sequencing technologies, the genomic features of most lymphoid neoplasms have been characterized at an unprecedented scale. Although the principles for...


Post-transplant Cyclophosphamide in Acute Leukemia Patients Receiving
more than 5/10 HLA-Mismatched Allogeneic Hematopoietic Cell
Transplantation from Related Donors: a Study on behalf of the ALWP of the
EBMT
Presenter: Prof. Spyridonidis
Participants: Dr Liga, Dr Valera, Dr Tsokanas, A. Christopoulou
Duration: 40 mins


Presenter: Prof. Spyridonidis
Participants: Dr Liga, Dr Valera, Dr Tsokanas, A. Christopoulou, E. Sagiadinou
Duration: 40 mins
Indications for haematopoietic cell transplantation for
haematological diseases, solid tumours and immune disorders:
current practice in Europe, 2022



